Importantly, blocking IGF1‐IGF1R signaling reversed the effects of Rack1 deficiency on AD pathology in mice, thereby identifying a novel critical signaling pathway in microglia‐astrocyte crosstalk and suggesting a potential therapeutic target for AD treatment. Here, IGF1R is linked to Alzheimer disease.